Shares of
Provention Bio
soared Monday after the biopharmaceutical company agreed to be acquired by France’s
Sanofi
(SNY) for $25 a share, or about $2.9 billion.
Provention Bio (ticker: PRVB), which focuses on autoimmune diseases, jumped 260% to $24.14 in premarket trading Monday. The stock closed Friday at $6.70. American depositary receipts of Sanofi fell 0.3%.
Source: https://www.barrons.com/articles/provention-bio-stock-sanofi-acquisition-7f5a2c9d?siteid=yhoof2&yptr=yahoo